Quarterly report pursuant to Section 13 or 15(d)

License Agreements (Details)

v3.8.0.1
License Agreements (Details)
Feb. 16, 2018
USD ($)
product_formulation
Avadel Ireland | LiquiTime Licensing and Development Agreement  
Asset Acquisition And License Agreement [Line Items]  
Number of product formulations | product_formulation 4
Product royalty 6.00%
TRIS Pharma | Karbinal Agreement  
Asset Acquisition And License Agreement [Line Items]  
Product royalty 23.50%
Contract term 20 years
Make whole payment, percent 8.50%
Potential milestone revenue threshold $ 40,000,000
Potential milestone payment $ 3,000,000
Eisai Inc | AcipHex Agreement  
Asset Acquisition And License Agreement [Line Items]  
Product royalty 15.00%
Potential milestone revenue threshold $ 50,000,000
Yung Shin Pharm. Ind, Co | Cefaclor  
Asset Acquisition And License Agreement [Line Items]  
Product royalty 15.00%
Potential milestone revenue threshold $ 40,000,000
Automatic renewal period 12 months
Maximum | TRIS Pharma | Karbinal Agreement  
Asset Acquisition And License Agreement [Line Items]  
Make whole payment $ 750,000
Maximum | Eisai Inc | AcipHex Agreement  
Asset Acquisition And License Agreement [Line Items]  
Potential milestone payment $ 8,000,000
Royalty payment period 5 years
Maximum | Yung Shin Pharm. Ind, Co | Cefaclor  
Asset Acquisition And License Agreement [Line Items]  
Potential milestone payment $ 6,500,000